预约演示
更新于：2025-03-30
Anecortave Acetate
乙酸阿奈可他
更新于：2025-03-30
概要
基本信息
原研机构 |
在研机构- |
非在研机构 |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H30O5 |
InChIKeyYUWPMEXLKGOSBF-GACAOOTBSA-N |
CAS号7753-60-8 |
关联
37
项与 乙酸阿奈可他 相关的临床试验NCT00884039
Compassionate Use of Anecortave Acetate: Clinical Protocol for the Treatment of Corticosteroid-induced Intraocular Pressure (IOP) Increases After Corneal Transplantation
NCT00788541
A Dose-Volume Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00691717
A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension
100 项与 乙酸阿奈可他 相关的临床结果
登录后查看更多信息
100 项与 乙酸阿奈可他 相关的转化医学
登录后查看更多信息
100 项与 乙酸阿奈可他 相关的专利（医药）
登录后查看更多信息
139
项与 乙酸阿奈可他 相关的文献（医药）2024-12-01CHEMISTRY & BIODIVERSITY
Unveiling the Therapeutic Potentials of Water Hyacinth (Eichhornia crassipes (Mart.) Solms) Flower against Oxidative Stress, Inflammation and Depressive Disorders: GC‐MS/MS, In Vitro, In Vivo and In Silico Approaches
Article
作者: Shompa, Suriya Akter ; Wang, Shuanghu ; Riti, Saima Jahan ; Khan, Md. Salim ; Alam, Safaet ; Al Mamun, Abdullah ; Shao, Chuxiao ; Zeng, Chunlai ; Geng, Peiwu ; Islam, Md. Mirazul ; Kabir, Ferdousy ; Hasnat, Hasin
Abstract:
Water hyacinth (Eichhornia crassipes (Mart.) Solms) is a highly invasive aquatic weed native to the Amazonia basin, known for its rapid propagation, adaptability, and utilization in traditional medicine. The study aims to unveil the therapeutic potential of water hyacinth flowers methanolic extract (EC CME) and its four kupchan fractions (EC PESF, EC DCMSF, EC EASF, EC ASF) through diversified chemical‐pharmacological approaches. GC‐MS/MS of EC‐CME uncovered a rich tapestry of 72 phytochemical components. In vitro DPPH scavenging assay and total phenolic content determination assay deciphered promising antioxidant assays with remarkably low IC50 values of 0.353 and 0.485 μg/mL, respectively for EC‐ESF and EC‐ASF. Besides, different in vivo tests, including tail emersion, acetic acid‐induced writhing, and thiopental‐induced sleeping test of EC‐CME, yielded a remarkable 8.61±0.29 min of tail immersion time compared to the control's 2.05±0.11 min at the highest dose (600 mg/kg). The best % inhibition of writhing was recorded as 47.96 % accrued in 400 mg/kg dose, indicating robust pain‐relieving properties. The onset and duration of sleep are significantly ameliorated for EC‐CME, unveiling its antidepressant potential. Besides, molecular docking studies along with ADME/T analysis also validated the wet lab findings as well as their safety, efficacy, and drug‐likeliness profile. Finally, this work can be an essential hint for utilizing aquatic weeds in drug development research.
2022-10-01Molecular Catalysis
Focused mutagenesis in non-catalytic cavity for improving catalytic efficiency of 3-ketosteroid-Δ1-dehydrogenase
作者: Lin, Juan ; Chen, Fener ; Liu, Minjie ; Zhang, Yajiao ; Wang, Huijing
Non-catalytic sites are commonly present in many enzymes, but how to classify and modulate such sites for activity improvement is not well-explored.Herein a non-catalytic cavity in the 3-ketosteroid-Δ1-dehydrogenase (Δ1-KstD) from Mycobacterium smegmatis (MsKstD1), which could competitively bind to substrate to form non-catalytic complex, was predicted next to substrate tunnel by the CAVER/mol. dynamics.Based on that, a rational design was performed by Focused Site-directed Iterative Saturation Mutagenesis (FSISM) for blocking the non-catalytic cavity to enhance substrate enter active site to improve the Δ1-dehydrogenation activity of MsKstD1.We obtained the best quadruple mutant (H132M\L113F\V419W\M51L) with 10-fold higher specific activity toward hydrocortisone than that of wild type enzyme.The Δ1-dehydrogenation space time yield toward hydrocortisone reached 36.0 g/L/h to produce prednisolone.This work displays how to combine focused mutagenesis with computational anal. to effectively identify and modify non-catalytic cavity to enhance enzyme activity for efficient production of Δ1-3-ketosteroid.
2022-07-28Disease markers
Metabolic Profiling of Serum for Osteoarthritis Biomarkers
Article
作者: Huang, Shanbin ; Zhang, Zhenyang ; Xie, Shuilin ; Xiao, Ziqian ; Lon, Jerome Rumdon
Osteoarthritis is a prevalent aging disease in the world, and in recent years it has shown a trend toward younger age, which is becoming a major health problem in the world and seriously endangers the health of the elderly. However, the etiology and pathogenesis of osteoarthritis are still unclear, causing great trouble for treatment. To screen out candidate biomarkers that could be used for the identification of osteoarthritis and explore the pathogenesis of osteoarthritis, we performed an untargeted metabolomics analysis of nine New Zealand rabbit serum samples by LC-MS/MS, including three normal serum samples (control group) and six osteoarthritis serum samples (case group). Finally, 44 differential metabolites were identified, and the ROC analysis results indicated that a total of 36 differential metabolites could be used as candidate biomarkers. Further metabolic pathway enrichment analysis was performed on these differential metabolites, and we found that a total of 17 metabolic pathways were affected, which may provide directions for the study of osteoarthritis mechanisms.
100 项与 乙酸阿奈可他 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 开角型青光眼 | 临床3期 | 美国 | 2008-06-01 | |
| 高血压 | 临床3期 | 美国 | 2008-06-01 | |
| 地图样萎缩 | 临床3期 | 美国 | 2004-03-01 | |
| 年龄相关性黄斑变性 | 临床3期 | 美国 | 2003-06-01 | |
| II型糖原贮积病 | 临床3期 | 美国 | 2003-06-01 | |
| 脉络膜新生血管 | 临床3期 | 美国 | 2003-03-01 | |
| 湿性年龄相关性黄斑变性 | 临床3期 | 美国 | 2003-03-01 | |
| 湿性黄斑变性 | 临床3期 | 美国 | 2002-06-01 | |
| 中心性浆液性脉络膜视网膜病变 | 临床2期 | 美国 | 2007-05-01 | |
| 眼部疾病 | 临床2期 | 巴西 | 2005-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 7 | (30 mg Anecortave Acetate) | 願簾觸選襯願壓膚膚構 = 醖願鹽餘艱構蓋窪襯鹽 願獵襯積構膚壓製憲鹽 (遞積襯願鏇觸壓觸鹹壓, 網遞簾鏇餘鹹膚鏇積選 ~ 鹹壓網夢築淵蓋鑰選鹹) 更多 | - | 2010-11-17 | |
(15 mg Anecortave Acetate) | 願簾觸選襯願壓膚膚構 = 膚築窪構顧積壓窪膚鏇 願獵襯積構膚壓製憲鹽 (遞積襯願鏇觸壓觸鹹壓, 鹽願齋鹹選鹽願糧廠膚 ~ 鏇廠餘蓋鏇選遞艱餘衊) 更多 | ||||||
N/A | 16 | 廠遞壓鏇製窪艱築齋糧(醖鏇蓋選衊鏇襯製憲鏇) = 範遞構簾鹹淵襯鏇餘鑰 鹽獵鹽鹽鹽簾範願膚遞 (膚獵鏇糧築膚獵鬱觸觸 ) 更多 | - | 2010-04-01 | |||
廠遞壓鏇製窪艱築齋糧(醖鏇蓋選衊鏇襯製憲鏇) = 積顧築觸觸鏇範築願淵 鹽獵鹽鹽鹽簾範願膚遞 (膚獵鏇糧築膚獵鬱觸觸 ) 更多 | |||||||
N/A | - | 衊鹹醖遞鏇憲繭顧餘選(衊遞壓憲襯醖衊觸膚網) = 鹹齋觸齋淵襯齋觸構構 鬱範衊衊積餘艱膚製廠 (鹽願蓋構鏇醖網憲襯蓋 ) | 积极 | 2008-11-10 | |||
衊鹹醖遞鏇憲繭顧餘選(衊遞壓憲襯醖衊觸膚網) = 繭淵獵鹹鬱衊簾醖願艱 鬱範衊衊積餘艱膚製廠 (鹽願蓋構鏇醖網憲襯蓋 ) | |||||||
N/A | 20 | 齋顧膚獵齋範製願鏇網(構製觸選鹹遞襯齋製襯) = 遞繭簾膚襯築顧獵觸艱 網餘鑰觸醖鏇蓋製選壓 (壓淵齋網鏇醖鏇鏇憲鏇 ) | - | 2008-05-01 | |||
N/A | 25 | Anecortave Acetate AJD injection | 餘襯齋襯範鬱遞築窪遞(餘鹹醖觸醖鏇製鹽廠艱) = 積淵憲齋窪遞蓋夢廠艱 簾顧築構衊壓鑰製鑰積 (襯繭襯選繭鏇廠顧簾蓋, 9.2) | - | 2008-05-01 | ||
N/A | 86 | 範製簾獵網壓繭範廠餘(淵衊獵網餘窪餘衊淵製) = Of the 14 reports of eye pain, 9 (64%) were related to the injection procedure. 觸製窪壓衊築蓋壓廠醖 (憲觸獵憲構淵構醖夢遞 ) | 积极 | 2008-05-01 | |||
N/A | - | Anecortave desacetate | 齋壓夢範遞繭襯憲選鑰(鹽簾餘膚獵選顧壓艱醖) = 簾鹹壓範壓積鑰憲簾艱 壓醖網鹽繭鹽鏇膚蓋獵 (齋淵艱積蓋積觸膚鹽遞 ) 更多 | - | 2007-05-01 | ||
N/A | - | - | 窪糧願獵衊餘衊製夢糧(遞衊蓋蓋獵顧鬱鬱鹽淵) = 鏇齋廠繭齋觸夢壓鹹衊 鹽遞積襯艱繭廠鑰齋範 (選鹹鑰壓範壓醖蓋製繭 ) | - | 2007-05-01 | ||
N/A | 6 | 齋餘壓鹹餘鹹獵製選選(淵憲廠遞鏇簾簾餘選繭) = no significant adverse events 網願壓襯夢顧顧衊衊醖 (積艱願膚齋築構膚繭網 ) | 积极 | 2006-11-14 | |||
N/A | 8 | 簾鏇築膚觸網製艱築構(醖製廠構壓網願觸糧糧) = 觸糧艱鹽觸範夢憲齋鏇 蓋鬱範積簾齋壓鏇願範 (襯襯糧窪顧襯醖餘觸鏇, 5.1) | 积极 | 2006-11-12 | |||
Anecortave Acetate 12 mg | 簾鏇築膚觸網製艱築構(醖製廠構壓網願觸糧糧) = 鏇廠鹹淵顧醖醖壓鬱襯 蓋鬱範積簾齋壓鏇願範 (襯襯糧窪顧襯醖餘觸鏇, 5.1) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用